Primary Results from Phase 3 EVOKE-03/KEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC
G. Mountzios1, M. Tiseo2, N. Katakami3, T. Ciuleanu4, S. Lu5, D. Kowalski6, J.C-H. Yang7, M.A.N. Sendur8, S. Ahmed9, S. Baka10, M. Janning11, X. Yu12, Y. Li12, Y. Sidi13, J. Yuan13, M. Moskovitz14
1Henry Dunant Hospital Center, Athens/GR ,2Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica, Parma/IT ,3Takarazuka City Hospital, Takarazuka, Hyogo,/JP ,4Institutul Oncologic-Oncologie
|